Thursday brought a fresh batch of coverage initiations from Wall Street analysts, with five companies getting their first ratings from various firms. The headliner? A bullish take on Astera Labs Inc (ALAB) that sees substantial upside ahead.

BNP Paribas Exane analyst Karl Ackerman launched coverage on Astera Labs (ALAB) with an Outperform rating and set a price target of $225. That's a hefty vote of confidence considering the stock closed at $142.01 on Wednesday, implying roughly 58% upside if Ackerman's thesis plays out.

But Astera Labs wasn't the only company getting analyst attention. Here's the full rundown of Thursday's coverage initiations:

Piper Sandler analyst Clarke Jeffries started coverage on Roper Technologies Inc (ROP) with an Overweight rating and a $600 price target. The industrial technology company closed at $444.78 on Wednesday, so Jeffries is betting on about 35% appreciation from current levels.

Over in the quantum computing space, JP Morgan analyst Peter Peng initiated IONQ Inc (IONQ) with a Neutral rating and a $47 price target. This one's interesting because IonQ shares closed at $47.88 on Wednesday, meaning Peng sees the stock as essentially fairly valued right now.

Rothschild & Co analyst Natalya Davies kicked off coverage on Bruker Corp (BRKR) with a Buy rating and a $60 price target. Bruker shares finished Wednesday's session at $43.39, giving Davies' target about 38% upside potential.

Finally, Evercore ISI Group analyst Cory Kasimov initiated coverage on ORIC Pharmaceuticals Inc (ORIC) with an Outperform rating and a $25 price target. The biotech stock closed at $11.48 on Wednesday, making this the most aggressive call of the bunch with an implied upside of more than 115%.

Four out of five initiations came with bullish ratings, which tells you something about how these analysts view the opportunity set. Whether they're right or not, we'll find out soon enough. That's the thing about price targets—they're testable predictions, not just vibes.